Geerts 1994.

Methods	Six‐week randomised, double‐blind study
Participants	In‐ and outpatients fulfilling DSM‐III‐R criteria for major depression without psychotic features, with a score of at least 17 on the Hamilton Rating Scale for Depression‐17 item (HDRS‐17). Age range: 18‐70 years Exclusion criteria: suicidal intent, any other psychiatric illness, severe organic disease, alcoholism and drug abuse, use of MAOI in the preceding 2 week, use of an antidepressant drug in the previous 4 days, or any investigational drug in the preceding 4 weeks, patients who ever received fluoxetine or moclobemide.
Interventions	Fluoxetine: 25 participants Moclobemide: 24 participants Fluoxetine dose range: 20‐40 mg/day Moclobemide dose range: 300‐600 mg/day Only lithium and bromazepam were allowed
Outcomes	Final score of less than 10 or a decrease of at least 50% from baseline on the HDRS‐17, Clinical Global Impression (CGI)
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double‐blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote:"patients received capsules of identical appearance and taste", no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double‐blind, no further information
Incomplete outcome data (attrition bias) All outcomes	High risk	End‐point scores reported without denominators. Analysis of HDRS scores were based on completers, instead of on randomised patients
Selective reporting (reporting bias)	Unclear risk	Number and reasons of withdrawals reported. Adverse effects reported
Other bias	High risk	Last author's affiliation was Roche Industry and this company produces moclobemide